🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/08/2002 | 22,07 | 23,96 | 21,93 | 23,68 | +7,54% | 9,20% | 1.218.200 |
| 20/08/2002 | 21,22 | 22,57 | 20,99 | 22,02 | +3,48% | 7,45% | 685.400 |
| 19/08/2002 | 21,54 | 22,10 | 20,67 | 21,28 | -1,98% | 6,64% | 651.300 |
| 16/08/2002 | 22,36 | 22,37 | 21,16 | 21,71 | -2,91% | 5,41% | 819.600 |
| 15/08/2002 | 20,89 | 22,83 | 20,89 | 22,36 | +6,99% | 9,29% | 1.639.800 |
| 14/08/2002 | 19,41 | 20,90 | 18,76 | 20,90 | +7,12% | 11,03% | 778.500 |
| 13/08/2002 | 20,05 | 20,55 | 19,22 | 19,51 | -3,65% | 6,63% | 873.700 |
| 12/08/2002 | 19,20 | 20,62 | 18,89 | 20,25 | +4,92% | 9,01% | 457.300 |
| 09/08/2002 | 18,99 | 19,96 | 18,80 | 19,30 | -1,18% | 6,11% | 962.400 |
| 08/08/2002 | 18,70 | 19,55 | 18,13 | 19,53 | +6,26% | 7,59% | 1.015.600 |
| 07/08/2002 | 18,57 | 19,05 | 17,39 | 18,38 | +0,71% | 8,94% | 1.113.300 |
| 06/08/2002 | 17,31 | 18,31 | 17,30 | 18,25 | +6,60% | 5,83% | 839.500 |
| 05/08/2002 | 18,39 | 18,80 | 17,10 | 17,12 | -7,11% | 9,24% | 654.700 |
| 02/08/2002 | 18,51 | 19,35 | 17,60 | 18,43 | -0,75% | 9,45% | 678.800 |
| 01/08/2002 | 19,60 | 19,91 | 18,57 | 18,57 | -5,93% | 6,84% | 594.300 |
| 31/07/2002 | 19,67 | 20,83 | 19,41 | 19,74 | -0,05% | 7,22% | 1.193.200 |
| 30/07/2002 | 18,47 | 19,93 | 17,67 | 19,75 | +6,76% | 12,24% | 1.050.000 |
| 29/07/2002 | 17,52 | 18,87 | 17,30 | 18,50 | +5,84% | 8,96% | 908.700 |
| 26/07/2002 | 16,95 | 18,35 | 16,45 | 17,48 | +3,13% | 11,21% | 980.800 |
| 25/07/2002 | 16,76 | 18,27 | 16,32 | 16,95 | +1,80% | 11,63% | 1.206.100 |
| 24/07/2002 | 15,38 | 16,84 | 14,60 | 16,65 | +6,73% | 14,56% | 1.628.800 |
| 23/07/2002 | 16,01 | 16,74 | 15,11 | 15,60 | -1,45% | 10,18% | 951.800 |
| 22/07/2002 | 15,46 | 16,55 | 15,20 | 15,83 | +0,51% | 8,73% | 1.073.400 |
| 19/07/2002 | 15,94 | 15,94 | 14,85 | 15,75 | +0,32% | 6,84% | 1.211.900 |
| 18/07/2002 | 16,50 | 16,69 | 15,28 | 15,70 | -4,68% | 8,55% | 620.000 |
| 17/07/2002 | 16,05 | 17,21 | 15,66 | 16,47 | +5,58% | 9,66% | 912.700 |
| 16/07/2002 | 14,95 | 17,12 | 14,70 | 15,60 | +5,12% | 16,19% | 1.239.300 |
| 15/07/2002 | 14,52 | 15,01 | 14,11 | 14,84 | +2,49% | 6,20% | 571.300 |
| 12/07/2002 | 14,25 | 15,24 | 14,00 | 14,48 | +1,26% | 8,70% | 595.700 |
| 11/07/2002 | 13,03 | 14,34 | 12,70 | 14,30 | +10,42% | 12,59% | 1.047.700 |